Early nutritional screening may benefit patients receiving vismodegib
the ONA take:
Early nutritional screening may be beneficial in patients with locally advanced or metastatic basal cell carcinoma receiving vismodegib, a new study published online ahead of print in the journal Supportive Care in Cancer has suggested.
Although vismodegib is effective in the treatment of this type of skin cancer, weight loss and dysgeusia (persistent abnormal taste or change in taste) are common treatment-related adverse events.
Therefore, researchers sought to monitor the nutritional status of vismodegib-treated patients, as well as assess the incidence of dysgeusia and the benefit of early nutritional management.
For the prospective study, researchers enrolled 45 patients with locally advanced or metastatic basal cell carcinoma who started vismodegib between October 2011 and May 2013 at Nantes University Hospital in France.
Of those, 24 patients had not received any specific nutritional management while 21 patients were evaluated by a physician from the Nutrition Support Unit and received dietary counseling at the time of vismodegib initiation.
Results showed that 24% of patients receiving dietary counseling were undernourished at vismodegib initiation and the 6-month cumulative incidence of dysgeusia was 71%.
Researchers found that 38% of patients receiving dietary counseling experienced a weight loss greater than 5% compared with 54% of those who did not receive any specific nutritional management.
“The potential benefit of nutritional support in this setting warrants further investigation,” the authors conclude.
Early nutritional screening may be beneficial in patients with locally advanced or metastatic basal cell carcinoma receiving vismodegib.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|